Deals

Iambic hands its cancer-pill gamble to Nasdaq after $461.8M of private money

The Nvidia-backed AI drug-discovery company filed to list as IAM carrying a $77.3 million annual loss against $9.4 million of partnership revenue. The private holders get their public mark; public buyers fund the trials.

Vincent JiangVincent Jiangthree-minute read
Share
Two researchers in white lab coats work at a bench in a cancer research laboratory, one looking through a microscope while a third researcher reviews papers behind them
1 / 6Slide 1 of 6
Researchers at a cancer research laboratory. Iambic Therapeutics, which filed to list on Nasdaq as IAM, runs robotic labs that synthesize and test hundreds of compounds per program each week.

The blanks are the pricing fight

On Monday, 21 September 2026, Iambic Therapeutics filed its S-1 to list on Nasdaq as IAM, with J.P. Morgan, Jefferies, BofA Securities and Citigroup running the book 12. The share count and the price range are blank, and those blanks are where the two camps meet 1. Incorporated in 2019 as Entos, the San Diego company sells what it calls molecular superintelligence: AI models that design molecules, robotic labs that synthesize and test hundreds of compounds per program each week 2.

What the fresh cash buys

Renaissance Capital frames the raise at up to $100 million 3. Net proceeds plus existing cash go to three wholly owned cancer programs: IAM1363, an oral, brain-penetrant HER2 inhibitor in a Phase 1/1b trial with a registrational study possible as early as 2027, and IAM217 and IAM-C1, two preclinical candidates with US IND filings expected this quarter 2.

The ledger riding along

In 2025 Iambic booked $9.4 million of revenue against a $77.3 million net loss, after $1.2 million and $47.9 million in 2024 12. Trailing revenue reached $18 million through 30 June 2026 3. Every dollar so far is partnership money, not drug sales, and the S-1 concedes the platform has not yet led to an approved drug product 2.

The hole grew faster than the top line: Iambic's net loss outran revenue in both years

  • Revenue
  • Net loss
-$100M-$50M$0M$50M20242025Loss ran 8.2x revenue
Data
RevenueNet loss
2024$1.2M-$47.9M
2025$9.4M-$77.3M
Fiscal-year revenue and net loss, US$ millions, per Iambic's Form S-1 filed 21 September 2026 and contemporaneous coverage; losses drawn as negative. Sources: Iambic S-1; Benzinga via Yahoo Finance.1,2

Who gets the public mark

Private investors put in about $461.8 million through 18 September 2026; the holders above 5 percent are Catalio, Nexus Ventures, Q Healthcare Holding, Nvidia−2.32% — Nvidia, down 2.32 percent today and Coatue 2. Employees hold options on 17.2 million shares at a $1.31 weighted-average strike, and the filing states that prior investors bought at prices lower than the coming public price 2. One stated purpose of the offering is to "create a public market" and ease later sales by stockholders and employees 2.

The pharma hedge, and a window that keeps clearing

The hedge is in the payment terms. AbbVie, which announced its collaboration the same morning, pays an upfront and then success-based milestones and tiered royalties 4; Takeda's February 2026 deal carries success-based payments potentially above $1.7 billion, plus royalties 5. The partners pay when programs succeed, while IPO buyers hold the equity straight through failure. Jazz, Bayer, Lundbeck and Revolution Medicines sit on the same partner list 2.

Why does the 2026 window keep clearing filings whose losses run near eight times revenue? Because biotech is where the returns are: all five of this year's best-performing IPOs above $50 million are biotechs, with a wave of drugmaker acquisitions underwriting demand, in Renaissance strategist Matt Kennedy's count 6. The free pass may be narrowing anyway; Electra Therapeutics raised $350 million in an upsized IPO on Friday and closed down 11.7 percent, and Kennedy expects the sector to draw more scrutiny from here 7.

Second Nvidia-backed S-1 in three days

Nscale, the month's other Nvidia-backed filer, posted a $1.02 billion first-half loss on $140.6 million of revenue while chasing a reported $30 billion valuation 8, a cap table The Inference unpacked on Monday. Nvidia holds more than 5 percent of Iambic and appears in its partner roster alongside AbbVie and Takeda 2; whether that seat moves the eventual price is the one question the coming amendment will not answer. Watch the amendment that fills in the range, then the fourth-quarter INDs. The private money built the platform. The public money buys the trials.

Get Deals by email, free

The acquisitions, rounds and contracts that move AI money. In our daily email, every weekday.

Loading NVDA

More about NVIDIA

NVDAFiscal Q2 2027
Fiscal Q2 2027 · quarter to 26 Jul 2026 · changes vs a year earlier

Revenue rose 106% to $96.2B, 92.5% of it from Data Center, “driven by the ramp of our Blackwell Ultra infrastructure”. Gains on equity stakes of $7.8B lifted net income to $59.7B.

Revenue$96.2B▲ 106%
Gross margin75.0%▲ 2.6 pts
Operating margin66.2%▲ 5.4 pts
Net income$59.7B▲ 126%
Hyperscale$48.7B▲ 102%AI clouds & enterprise$40.3B▲ 138%Data Center$89.0B▲ 117%Edge Computing$7.2B▲ 27%Revenue$96.2B▲ 106%Gross profit$72.1B75.0% marginCost of revenue$24.1BOther income$7.8Bequity-stake gainsOperating income$63.7B66.2% marginOperating expenses$8.4BNet income$59.7B▲ 126%Tax$11.8B16.5% rateR&D$7.1BSG&A$1.4B
Show as a table
LineValue
Revenue$96.2B
Gross margin75.0%
Operating margin66.2%
Net income$59.7B
Hyperscale$48.7B
AI clouds & enterprise$40.3B
Data Center$89.0B
Edge Computing$7.2B
Gross profit$72.1B
Cost of revenue$24.1B
Other income$7.8B
Operating income$63.7B
Operating expenses$8.4B
Tax$11.8B
R&D$7.1B
SG&A$1.4B

Reader comments

0 comments

    Deals

    Salesforce agreed to pay $47.50 a share for Braze, whose SEC-filed FAQ leaves renewal terms undecided

    Three weeks after Salesforce agreed to buy Braze for $5.66 billion, the seller's own SEC-filed sales script promises enterprise buyers nothing beyond today's contracts while its account teams push multi-year renewals. For BRZE holders the stock is now a claim on $47.50 in cash, and the deal documents price the wait.

    Deals

    Musk puts a Tesla-SpaceX merger at 25% within a year

    Prediction-market odds put the announcement in early 2027, and the pay agreement Musk signed in 2025 lets a rich deal price vest shares no operating goal has earned. The cost lands on Tesla holders, who also own the deciding vote.

    Deals

    Sacramento votes to renew Axon for $17.7 million and bar AI training on city camera data

    The renewal makes Sacramento own its camera data, opt out of Axon's AI training and bar default sharing with federal agencies. Spread across renewals, those terms reach the data advantage beneath the software Axon's beaten-down stock now leans on.

    Deals

    Merck buys AI drug designs from Isomorphic Labs two days after its $5 billion round

    MSD, Merck & Co. (NYSE: MRK) outside the United States and Canada, carries the clinical and commercial risk and pays an undisclosed upfront, milestones and tiered royalties, while Isomorphic Labs holds a new option to co-fund trials for elevated royalties. Two days after the largest life-science venture round ever, the deal hands Alphabet's (Nasdaq: GOOGL) AI drug spinout its fourth Big Pharma payer before any candidate has entered a human trial.

    Deals

    AMD closed Taalas at $2.9 billion, with $1.4 billion riding on undisclosed milestones

    AMD's completion release named no price; the quarterly filing that carries the terms makes up to $1.4 billion of the $2.9 billion contingent on conditions the company has not disclosed. It is the second AI acquisition in a fortnight, about $11.1 billion combined, by a stock trading above 100 times trailing earnings.

    Deals

    Cognizant won Network Rail's seven-year data center contract 28% under the buyer's own estimate

    The seven-year data-center award hands Cognizant volume in a weak market, but the buyer's own tender estimate shows a large UK public-sector deal clearing about 28% below budget, and the award notice offers no explanation.

    Subscribe to TheInference for free